title: Are chimeric antigen receptor T cells ready for prime time?
authors.affiliation: Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Renier J
authors.initials: RJ
authors.lastname: Brentjens
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000276:immunology*; D002986:Clinical Trials as Topic; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000378:metabolism*; D011993:Recombinant Fusion Proteins; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins